Platelet-rich plasma in the treatment of hip osteoarthritis: a randomized, double-blinded, controlled trial

telet-rich plasma in the treatment of hip osteoarthritis: a randomized, double-blinded, controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026405

Enrollment

Unknown

Registered

2019-10-08

Start date

2019-11-01

Completion date

Unknown

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

platelet-rich plasma (PRP):platelet-rich plasma (PRP)

hyaluronic acid:hyaluronic acid

NS: saline solution

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with hip osteoarthritis.

Exclusion criteria

Exclusion criteria: 1. Patient aged less than 18 years; 2. History of hip operations; 3. History of hip intra-articular injections or oral NASID in the past 6 months; 4. Unable to receive pre-treatment assessment and post-treatment follow-up; 5. Patients with blood diseases.

Design outcomes

Primary

Measure	Time frame
Harris scores;	—

Countries

China

Contacts

Public ContactLiu Yan

West China Hospital, Sichuan University

123315971@qq.com+86 18190030357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026